相关实验视频

Updated: Sep 9, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

在轻度认知障碍中血清粉样蛋白β1-42和化-181水平升高:横截面研究

Song Gao¹, Min Zhang², Wenjie Xu¹

¹Department of General Practice, Heqing Community Health Service Center, Shanghai, China.

Journal of Alzheimer's disease : JAD

|August 28, 2025

概括

在轻度认知障碍 (MCI) 中,血清粉样β (Aβ) < sub> 1-42 和酸化tau (p-tau181) 水平升高. 这些蛋白质可以作为早期MCI检测的血液生物标志物.

科学领域:

生物化学
神经学
生物标志物发现

背景情况:

轻度认知障碍 (MCI) 是痴呆症的前体.
早期发现MCI对于及时干预至关重要.
需要可靠的MCI血液生物标志物.

研究的目的:

研究血清粉样β (Aβ) < sub>1-42和p-tau181水平与MCI之间的关联.
通过血液生物标志物建立早期MCI检测的基础.

主要方法:

纳入了128名60岁以上的受试者.
通过ELISA测量血清Aβ_1-42和p-tau181.
统计分析包括千平方,曼-惠特尼U和斯皮尔曼相关性测试.

主要成果:

在MCI组,血清Aβ_1-42和p-tau181水平显著上升.
在Aβ_1-42和MCI之间存在强烈的正相关性 (r=0.819,p<0.001).
在p-tau181和MCI之间的中等相关性 (r=0.426,p<0.001).
Aβ_1-42显示出高的诊断值 (AUC=0. 975).
p-tau181的诊断疗效是中等的 (AUC=0. 747).

结论:

血清Aβ_1-42和p-tau181水平与MCI显著相关.
这些蛋白质可以作为早期MCI检测的潜在血液生物标志物.

关键词:

阿尔茨海默病粉胺-β 1-42 生物标志物早期诊断轻微的认知障碍没有.

更多相关视频

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...